Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

New guidance from a team of health experts around the world proposes expanding the definition of obesity beyond the popular ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

LONDON – Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...

The rise of GLP-1 drugs is sending the Diageo share price lower. But Stephen Wright thinks investors should try to avoid ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

(MENAFN- GlobeNewsWire - Nasdaq) First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk ... Patients refractory to non-steroidal anti-inflammatory ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...